Baseline clinical, biological and electrocardiograms characteristics
| Overall population (n=118) | AL (1) (n=26) | Wild-type ATTR (2) (n=80) | Variant-type ATTR (3) (n=12) | P value | 1 versus 2 | Posthoc analysis 2 versus 3 | 3 versus 1 | |
| Baseline characteristic | ||||||||
| Age—years | 78±10 | 68±12 | 82±7 | 71±6 | <0.001 | <0.001 | <0.001 | 0.722 |
| Male gender, n (%) | 95 (81) | 18 (69) | 68 (85) | 9 (75) | 0.188 | . | ||
| Body mass index—kg/m2 | 25±3 | 24±3 | 26±3 | 26±2 | 0.116 | . | ||
| Systolic blood pressure—mm Hg | 131±20 | 120±19 | 134±20 | 139±17 | 0.010 | 0.010 | 0.260 | 0.007 |
| Diastolic blood pressure—mm Hg | 76±11 | 72±10 | 76±11 | 82±14 | 0.044 | 0.072 | 0.121 | 0.033 |
| Heart rate—bpm | 77±16 | 82±10 | 77±18 | 70±7 | 0.009 | 0.033 | 0.171 | <0.001 |
| Medical history, n (%) | ||||||||
| Current smoker | 1 (1) | 1 (4) | 0 | 0 | 0.170 | |||
| Hypertension | 58 (49) | 8 (31) | 45 (56) | 5 (42) | 0.069 | |||
| Dyslipidaemia | 35 (30) | 6 (23) | 26 (33) | 3 (25) | 0.617 | |||
| Diabetes | 13 (11) | 2 (8) | 11 (14) | 0 | 0.306 | |||
| Ischaemic heart disease | 25 (21) | 3 (12) | 22 (28) | 0 | 0.038 | 0.097 | 0.038 | 0.226 |
| NYHA class, n (%) | ||||||||
| NYHA 1 | 25 (21) | 5 (19) | 17 (21) | 3 (25) | 0.922 | |||
| NYHA 2 | 70 (59) | 15 (58) | 48 (60) | 7 (58) | 0.976 | |||
| NYHA 3 | 20 (17) | 5 (19) | 13 (16) | 2 (17) | 0.940 | |||
| NYHA 4 | 3 (3) | 1 (4) | 2 (3) | 0 | 0.784 | |||
| Medication, n (%) | ||||||||
| Diuretics | 76 (64) | 12 (46) | 60 (75) | 4 (33) | 0.002 | 0.006 | 0.004 | 0.463 |
| Tafamidis | 28 (24) | – | 20 (25) | 8 (67) | <0.001 | 0.004 | ||
| Biochemistry | ||||||||
| NT-proBNP—ng/L | 2423 (1105–4380) | 2108 (691–4645) | 2607 (1408–4675) | 1096 (221–3036) | 0.062 | |||
| Troponin—ng/L | 71±46 | 76±54 | 74±44 | 41±32 | 0.007 | 0.903 | 0.002 | 0.008 |
| eGFR—mL/min/1.73 m2 | 56±21 | 61±26 | 52±19 | 73±16 | 0.002 | 0.084 | 0.001 | 0.209 |
| ECG, n (%) | ||||||||
| Atrial fibrillation | 31 (26) | 2 (8) | 28 (35) | 1 (8) | 0.008 | 0.008 | 0.065 | 0.946 |
| Low voltage | 13 (11) | 8 (31) | 4 (5) | 1 (8) | 0.001 | <0.001 | 0.637 | 0.136 |
| Pseudo infarct pattern | 14 (12) | 4 (15) | 7 (9) | 3 (25) | 0.475 | |||
| Functional analysis | ||||||||
| Peak oxygen consumption—mL/min/kg | 15±5 | 16±5 | 14±5 | 17±6 | 0.087 | |||
Data are presented as number (percent), mean±SD if normally distributed or median (IQR) if not normally distribute.
AL, light chain amyloidosis; ATTR, transthyretin amyloidosis; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-hormone brain natriuretic peptide; NYHA, New York Heart Association.